Sign in
RGEN Stock Price, Chart, Stats & News
Repligen Corporation
Save
Repligen Corporation (RGEN) does not currently pay a dividend.
9.32B
Market cap
91.77x
Current P/E
62.11x
Forward P/E
RGEN chart
Fundamentals
Gross margin | 50.91% |
Operating margin | 7.57% |
Pretax margin | 8.45% |
Net margin | 6.62% |
Effective tax rate | 21.62% |
ROA | 1.66% |
ROE | 2.37% |
D/E | 0.33x |
Interest coverage ratio | 1.25x |
RGEN valuation
P/E | 91.77x |
P/S | 8.40x |
P/B | 2.96x |
P/CF | 53.01x |
P/FCF | 67.91x |
P/OCF | 53.01x |
PEG | 0.05x |
EV multiple | 34.42x |
About
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing.
Similar securities
Based on sector and market capitalization
Report issue